Volume 5, Issue 1 (6-2022)
2022, 5(1): 0-0 |
Back to browse issues page
Ethics code: IR.MEDILAM.REC.1400.034
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pakzad R, soltani S, zandi M, akhavanrezayat S, Hosseini Z, Malekifar P, et al . The Ocular manifestations in COVID-19 patients: a systematic review and meta-analysis. Journal title 2022; 5 (1)
URL: http://newresearch.medilam.ac.ir/article-1-1287-en.html
URL: http://newresearch.medilam.ac.ir/article-1-1287-en.html
Reza Pakzad , Saber Soltani , Milad Zandi , Sara Akhavanrezayat , Zeinab Hosseini , Pooneh Malekifar , Iraj Pakzad , Habib Kakaei
Abstract: (2317 Views)
The ocular tropism of respiratory viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is reported, and studies showed ocular manifestations in coronavirus disease 2019 (COVID-19) patient. The aims of the current systematic review and meta-analysis study will be to determine the prevalence of ophthalmic manifestation in COVID-19 patients.
We will be searched the literature in Medline, Scopus, Web of Science, and Embase from December 1, 2019, until December 5, 2020, by using the main following MeSH keywords "SARS-CoV-2" and "ocular manifestations." The prevalence and 95% confidence interval (CI) will be calculated using binomial distribution and random effects. The meta-regression method will be utilized to investigate the factors affecting the heterogeneity.
We will be searched the literature in Medline, Scopus, Web of Science, and Embase from December 1, 2019, until December 5, 2020, by using the main following MeSH keywords "SARS-CoV-2" and "ocular manifestations." The prevalence and 95% confidence interval (CI) will be calculated using binomial distribution and random effects. The meta-regression method will be utilized to investigate the factors affecting the heterogeneity.
Received: 2020/12/11 | Accepted: 2021/03/10 | Published: 2022/06/19
Send email to the proposal executer
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |